nitroflurbiprofen has been researched along with Bone Loss, Osteoclastic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Idris, AI; Ralston, SH; van't Hof, RJ | 1 |
| Del Soldato, P; Idris, AI; Ralston, SH; van't Hof, RJ | 1 |
| Armour, KE; Armour, KJ; Del Soldato, P; Ralston, SH; Torbergsen, AC; van 't Hof, RJ | 1 |
3 other study(ies) available for nitroflurbiprofen and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
The nitrosylated flurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action.
Topics: Actins; Animals; Apoptosis; Bone Resorption; Cytokines; Enzyme Activation; Flurbiprofen; Mice; Mitogen-Activated Protein Kinases; NF-kappa B; Nitroso Compounds; Osteoclasts; RANK Ligand; Signal Transduction | 2009 |
The flurbiprofen derivatives HCT1026 and HCT1027 inhibit bone resorption by a mechanism independent of COX inhibition and nitric oxide production.
Topics: Animals; Bone Resorption; Cells, Cultured; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Flurbiprofen; Humans; Mice; Nitric Oxide; Prostaglandin-Endoperoxide Synthases; Rabbits | 2004 |
Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Resorption; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Female; Flurbiprofen; In Vitro Techniques; Mice; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Ovariectomy; Spleen | 2001 |